A new vaccine promising protection against a mutant strain has been approved for clinical trials


On April 4, sinobio announced on the Hong Kong stock exchange that its novel coronavirusmRNA vaccine has been approved for clinical trials by the state medical products administration (sda).Preclinical research results show that the vaccine can induce for a variety of the world health organization recognized one of the important variants, including the current epidemic strains, high degree of neutralizing antibodies, and on the basis of the prototype of the development of the existing more than new crown vaccine broad-spectrum resistance is strong, can more effectively protect the body from infection by existing variants.”The safety and efficacy of novel coronavirusmRNA vaccine must be confirmed by clinical studies, and there is no guarantee that it will lead to the successful development or commercialization of novel coronavirusmRNA vaccine,” concino said.MRNA vaccines are introduced into the body that encode disease-specific antigens and use the protein synthesis mechanisms of the host cell to produce antigens that trigger an immune response.The mRNA vaccine is the most advanced third generation vaccine, which still needs to be developed to enhance its stability, regulate its immunogenicity, and develop new delivery technology.It is reported that the first generation of traditional vaccines mainly consists of inactivated vaccines and live attenuated vaccines, which are the most widely used.The second generation of new vaccines includes subunit vaccines and recombinant protein vaccines.It should be noted that on April 3, shiyao also announced that its novel coronavirusmRNA vaccine, SYS6006, has been approved by the sfda for clinical study.Up to now, there are three approved vaccine products of Concino in China, namely the recombinant Novel Coronavirus vaccine AD5-NCOV (adenovirus type 5 vector, Kweysa), bivalent meningococcal polysaccharide conjugate vaccine MCV2 and tetravalent meningitis conjugate vaccine MCV4, which were launched in February, June and December last year respectively.Source: Beijing Evening News as a whole/Dong Xianhe school reading/Dong Xianhe preliminary review/Zhang Yi Fengbin final review/Zhao Minend statement: unauthorized, prohibit reprinting, use of the public account original articles.Reprint please indicate from Hohhot Daily official wechat;This platform reprinted part of the content from the network, involving infringement please contact delete.News hotline: 0471-6564013 Advertising hotline: 0471-6564037 6564013

Leave a Reply

Your email address will not be published.